| Jeremy St Aubin, PT | |
|
612 Center Ave N, Ashley, ND 58413-7013 | |
| (701) 288-5243 | |
| Not Available |
| Full Name | Jeremy St Aubin |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist - Pediatrics |
| Location | 612 Center Ave N, Ashley, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548712516 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251P0200X | Physical Therapist - Pediatrics | 1179 (North Dakota) | Primary |
| 2251P0200X | Physical Therapist - Pediatrics | 1262 (South Dakota) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy St Aubin, PT Po Box 450, Ashley, ND 58413-0450 Ph: () - | Jeremy St Aubin, PT 612 Center Ave N, Ashley, ND 58413-7013 Ph: (701) 288-5243 |
News Archive
Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.
Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.
Reporting for Kaiser Health News, Harris Meyer writes: "In the fourth year of a depressed real estate market, experts say thousands of seniors remain unable to move into senior housing because they can't sell their homes quickly enough or for the price they need. The upshot: Greater pressure on families to pay for parents' and grandparents' placements, or to care for them themselves"
Choosing the right size and color of your bowls and plates could help you eat less, according to a new study in the Journal of Consumer Research.
Physicians have a new resource for managing disease in patients with early-stage breast cancer. Patients diagnosed with ductal carcinoma in situ - cancer that has not left the breast ducts - now have the benefit of a multi-gene analysis that considers gene patterns to individualize therapy and determine the chance for recurrence, potentially sparing the patient additional therapy.
› Verified 5 days ago